APR Applied Pharma Research s.a.

04.12.2019 – 12:22
FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa
Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-named APR-TD011 for treatment of ...
mehr
11.06.2019 – 12:00
29th EWMA Conference: Latest Clinical Data on Nexodyn® AOS Demonstrating Higher Healing Performance in Chronic Leg Ulcers Presented by Applied Pharma Research
Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa (APR) presented at the recent 29th conference of the European Wound Management Association (EWMA) in Göteborg, the results of a clinical study confirming Nexodyn® AcidOxidizing Solution (AOS) to promote the restart of the healing process in ...
mehr